| Literature DB >> 20018111 |
John N Lavis1, Michael G Wilson, Andrew D Oxman, Simon Lewin, Atle Fretheim.
Abstract
This article is part of a series written for people responsible for making decisions about health policies and programmes and for those who support these decision makers. Policymakers and those supporting them often find themselves in situations that spur them on to work out how best to define a problem. These situations may range from being asked an awkward or challenging question in the legislature, through to finding a problem highlighted on the front page of a newspaper. The motivations for policymakers wanting to clarify a problem are diverse. These may range from deciding whether to pay serious attention to a particular problem that others claim is important, through to wondering how to convince others to agree that a problem is important. Debates and struggles over how to define a problem are a critically important part of the policymaking process. The outcome of these debates and struggles will influence whether and, in part, how policymakers take action to address a problem. Efforts at problem clarification that are informed by an appreciation of concurrent developments are more likely to generate actions. These concurrent developments can relate to policy and programme options (e.g. the publication of a report demonstrating the effectiveness of a particular option) or to political events (e.g. the appointment of a new Minister of Health with a personal interest in a particular issue). In this article, we suggest questions that can be used to guide those involved in identifying a problem and characterising its features. These are: 1. What is the problem? 2. How did the problem come to attention and has this process influenced the prospect of it being addressed? 3. What indicators can be used, or collected, to establish the magnitude of the problem and to measure progress in addressing it? 4. What comparisons can be made to establish the magnitude of the problem and to measure progress in addressing it? 5. How can the problem be framed (or described) in a way that will motivate different groups?Entities:
Year: 2009 PMID: 20018111 PMCID: PMC3271831 DOI: 10.1186/1478-4505-7-S1-S4
Source DB: PubMed Journal: Health Res Policy Syst ISSN: 1478-4505
Figure 1Clarifying evidence needs
Clarifying the problem underpinning the lack of widespread use of the recommended malaria treatment
| Members of the Evidence-Informed Policy Networks (EVIPNet) in ten sub-Saharan African countries identified the problem of the lack of widespread use of the recommended artemisinin-based combination therapy (ACT) to treat malaria in their respective countries. The following framework of four questions (and relevant sources of data and research evidence) [ |
| • Does the problem relate to a risk factor, disease or condition? |
| ◊ Incidence of (and death rates from) uncomplicated falciparum malaria, by age (including separately for infants), sex (including separately for pregnant women and lactating women), HIV status, malnutrition status, and socio-economic status |
| • Does the problem relate to a programme, service or drug currently being used to address a risk factor, disease or condition? |
| ◊ Cure rates for, and drug resistance (or reduced drug sensitivity) to, ACT and other anti-malarial drugs, as well as the side effects and costs of the drugs |
| ◊ The views and experiences of patients about particular anti-malarial drugs |
| • Does the problem relate to the current health system arrangements within which programmes, services and drugs are provided? |
| ◊ Governance arrangements |
| – Regulations about which ACT and other anti-malarial drugs (i.e. drugs, dosage regimes, and packaging) can be registered/licensed for sale, how counterfeit or substandard drugs are safeguarded against, how patents for them and profits arising from them are handled, how they can be marketed, who can prescribe them and how, and who can sell or dispense them and how |
| – National treatment guidelines and/or the national malaria control policy about the first-line (and second-line) drug therapy recommended for uncomplicated falciparum malaria, as well as their dosage regimes/packaging, targeting for particular populations, and targeting for areas with particular characteristics |
| – National essential drugs list, particularly the list of anti-malarial drugs |
| ◊ Financial arrangements |
| – Drug and dispensing fees for first-line drug therapy (and for ACT if this is not the first-line therapy) for uncomplicated falciparum malaria, including any subsidies for particular populations, remuneration arrangements for health works prescribing and dispensing ACT |
| – The views and experiences of patients about fees and subsidies and about financial incentives to promote adherence |
| ◊ Delivery arrangements |
| – Access rates for first-line drug therapy (and for ACT if this is not first-line therapy) for uncomplicated falciparum malaria (i.e. who has access to someone who can dispense drug therapy) |
| – Coverage rates for first-line drug therapy (and for ACT if this is not first-line therapy) for uncomplicated falciparum malaria (i.e. who is dispensed which drug) |
| – Treatment patterns for uncomplicated falciparum malaria (i.e. who dispenses what, when, where and how, including whether treatment is part of the Integrated Management of Childhood Illness or other ‘horizontal’ programmes) |
| – Adherence patterns for the treatment of uncomplicated falciparum malaria (i.e. who takes what, when, where and how) |
| – Arrangements for surveillance, pharmacovigilance and the diagnosis and treatment of atypical cases |
| – The views and experiences of patients about particular providers (or delivery arrangements more generally) |
| • Does the problem relate to the current degree of implementation of an agreed-upon course of action? |
| ◊ For example, regulations can only help to address a problem if they are acted upon throughout the health system. Regulations may exist about the registration/licensure, marketing, prescribing and dispending of ACT and other anti-malarial drugs. However, if the regulations are not enforced, there may be many counterfeit or substandard drugs in circulation, false statements may be made in drug advertisements, and untrained individuals may be prescribing or dispending ACT |
| The EVIPNet teams all concluded that the problem could be related to a risk factor, disease or condition, the programmes, services or drugs currently being used, the current health system arrangements and, in some cases, the current degree of implementation of an agreed-upon course of action. This had important implications for which options were considered appropriate to address this multi-faceted problem. |
Clarifying the problem underpinning high rates of medication error
| Questions 2-5 which were discussed earlier in this article can be used to clarify a problem once it has been related to one or more of the following: a risk factor, disease or condition, the programmes, services or drugs currently being used, the current health system arrangements and the current degree of implementation of an agreed upon course of action. Consider the following example of the problem of high rates of medication error: |
| • How did the problem come to attention and has this process influenced the prospect of it being addressed? |
| ◊ The problem of medical error may come to attention through a focusing event (e.g. a child dies because a doctor prescribes the wrong drug dosage), a change in an indicator (e.g. there is a dramatic increase in the number of reported errors in a given month) or feedback from the operation of current policies and programmes (e.g. an evaluation report identifies more types of medication errors than have been routinely measured) |
| ◊ An evaluation report may identify that one possible factor contributing to a problem is the lack of clear boundaries of the scope of practice between doctors, nurses and pharmacists, which makes accountability for prescribing, dispensing, administration and chart documentation unclear |
| ◊ The same report may propose that the problem be turned into a statement of purpose that can be used to engage a diverse array of stakeholders. For example, policymakers may prefer to speak about how their country will become a leader in patient safety, rather than referring to current patient safety problems |
| • What indicators can be used or collected to establish the magnitude of the problem and to measure progress in addressing it? |
| ◊ Policymakers may identify that no indicators are currently being measured accurately at the national level but that they are interested in starting to accurately measure both the number of medication error reports per quarter and the number of ‘near misses’ per quarter. Collecting such data would allow them to set a target level for the indicator |
| • What comparisons can be made in order to establish the magnitude of the problem and to measure progress in addressing it? |
| ◊ Policymakers may identify that they would like to make four types of comparisons: |
| – Comparisons over time within the country |
| – Comparisons to other appropriate comparator countries |
| – Comparisons against a target to be set as part of a national patient safety strategy |
| – Comparisons against what a national consumer association has said it would like to see |
| ◊ Ideally a search for administrative database studies or community surveys would allow the policymakers to identify at least some existing research evidence and allow them to make immediate comparisons |
| • How can a problem be framed (or described) in a way that will motivate different groups? |
| ◊ Policymakers may find that: |
| – Pharmacists respond to the language used to describe a medication error |
| – Consumer groups respond to a stated purpose of achieving, for example, a 50% reduction in medication errors |
| – Regulators engage when the lack of clear boundaries between the scope of practice of healthcare providers is discussed as an important feature of the problem |
| – Hospital staff may respond positively when told of a plan to collect an indicator that identifies under-reporting in a way does not penalise units or departments who support full disclosure |
| – Hospital executives may engage most fully when comparisons are made among their facilities |
| ◊ Ideally a search for qualitative studies would allow the policymakers to grasp the different meanings that different groups attach to a problem |
Finding research evidence about a problem
| While much of the task of problem clarification involves finding and using local evidence (the subject of Article 11 in this series), published administrative database studies and community surveys can provide insights about comparisons [ |
| The first set of steps involved in finding such studies includes: |
| • Drawing up a list of words or phrases that capture the problem (e.g. medication error, scope of practice), synonyms for each problem and factor (e.g. drug near-misses, professional regulation), and alternative spellings for each synonym (e.g. medication, medications) |
| • Deciding whether systematic reviews (the subject of Article 7) or single research studies are the focus of the search [ |
| • Providing any additional details that limit the search (e.g. children, adults) |
| The second set of steps includes: |
| • Choosing those words and phrases that would |
| • Choosing those words and phrases for which only one would need to be present (e.g. medical error and its synonyms), connecting them with ‘or’, and putting them in brackets, and |
| • Connecting both sets of brackets using ‘and’ |
| The third set of steps includes: |
| • Using the Internet to access the health-related database, PubMed. This database contains a ‘hedge’ (i.e. a validated search strategy or filter) for the types of studies of interest here [ |
| • Clicking on ‘special queries’ in the left task bar |
| • Clicking on ‘health services research’ queries |
| • Entering the words and phrases, as well as the Boolean operators (‘and’/‘or’) in the search field, and |
| • Clicking ‘process assessment’ or ‘outcomes assessment’ for administrative database studies and ‘qualitative research’ for qualitative studies |
| This approach increases the chances that the returned citations will be of the appropriate study type, though many other types of studies may be retrieved as well. |